The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Emerflu | Sanofi Pasteur S.A. | Influenza, Human; Immunization; Disease Outbreaks | 🇪🇺 EU | Order → |
| EnCyzix enclomifene | Renable Pharma Limited | Hypogonadism | 🇪🇺 EU 2018-01-25 | Order → |
| Enpaxiq Orphan | CTI Life Sciences Limited | Primary Myelofibrosis | 🇪🇺 EU | Order → |
| Entolimod TMC Entolimod | TMC Pharma Services Ltd | Acute Radiation Syndrome | 🇪🇺 EU | Order → |
| Enzalutamide Accordpharma enzalutamide Generic | Accord Healthcare | Prostatic Neoplasms | 🇪🇺 EU 2025-11-13 | Order → |
| Epixram levetiracetam | Neuraxpharm Pharmaceuticals S.L. | Epilepsy; Epilepsy, Generalized; Myoclonic Epilepsy, Juvenile | 🇪🇺 EU | Order → |
| Epjevy Orphan | CTI Life Sciences Limited | Primary Myelofibrosis | 🇪🇺 EU | Order → |
| Epostim epoetin alfa Biosimilar | Reliance GeneMedix Plc | Anemia | 🇪🇺 EU | Order → |
| Erlotinib Accord erlotinib Generic | Accord Healthcare S.L.U. | Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms | 🇪🇺 EU | Order → |
| Ertapenem Hospira ertapenem Generic | Hospira UK Limited | Bacterial Infections | 🇪🇺 EU | Order → |
| Ethyl Eicosapent soft gelatin capsules Orphan | Amarin Neuroscience Ltd | 🇪🇺 EU | Order → | |
| Evlarco obicetrapib;ezetimibe | A. Menarini International Licensing S.A. | Hypercholesterolemia; Dyslipidemias | 🇪🇺 EU 2026-07-23 | Order → |
| Exkivity mobocertinib | Takeda Pharma A/S | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU | Order → |
| Exondys eteplirsen Orphan | AVI Biopharma International Ltd | Muscular Dystrophy, Duchenne | 🇪🇺 EU 2018-09-20 | Order → |
| Exulett | Pfizer Limited | Skin Diseases, Infectious; Staphylococcal Infections; Soft Tissue Infections | 🇪🇺 EU | Order → |
| Factive | Menarini International Operations Luxembourg S.A. | Bronchitis, Chronic; Pneumonia, Bacterial | 🇪🇺 EU | Order → |
| Faldaprevir Boehringer Ingelheim faldaprevir | Boehringer Ingelheim International GmbH | Hepatitis C, Chronic | 🇪🇺 EU | Order → |
| Fanaptum iloperidone | Vanda Pharmaceuticals Ltd | Schizophrenia | 🇪🇺 EU 2017-11-09 | Order → |
| Fanaptum iloperidone | Vanda Pharmaceuticals Ltd | Schizophrenia | 🇪🇺 EU | Order → |
| Fanskya Mozafancogene autotemcel OrphanPRIMEATMP | Rocket Pharmaceuticals B.V. | Fanconi Anemia | 🇪🇺 EU | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.